Table 1 Trials conducted in China
Study ID | Location | Drug | Combination therapy | Participants in placebo groups, N | Average age, years | Gender, male, % | Duration of diabetes, years | Baseline HbA1c, % | Change of HbA1c in placebo groups, % | Duration, weeks | Jadad score |
|---|---|---|---|---|---|---|---|---|---|---|---|
Yang [11] | China | Sitagliptin | Metformin | 198 | 55 | 55 | 7.30 | 8.50 | -0.14 | 24 | 5 |
NCT01076088 [12] | China | Sitagliptin | None | 127 | 40 | 68 | / | 8.97 | -0.59 | 24 | / |
Metformin | 126 | 57 | 55 | 8.69 | -1.29 | ||||||
Metformin | 124 | 49 | 60 | 8.67 | -1.56 | ||||||
NCT01177384 [13] | China | Sitagliptin | Acarbose | 189 | 57 | 51 | / | 8.08 | -0.14 | 24 | / |
Mohan [14] | China | Sitagliptin | / | 82 | 51 | 60 | 1.70 | 8.60 | -0.20 | 18 | 5 |
Pan [6] | China | Vildagliptin | Metformin | 144 | 54 | 46 | 5.15 | 8.01 | -0.54 | 24 | 3 |
Yang [15] | China | Vildagliptin | Glimepiride | 136 | 59 | 58 | 6.90 | 8.70 | -0.20 | 24 | 4 |
Zeng [16] | China | Linagliptin | Metformin & sulphonylurea | 48 | 57 | 52 | >5 | 8.13 | 0.08 | 24 | 3 |
NCT01289119 [17] | China | Alogliptin | None | 93 | 53 | 58 | 2.12 | / | -0.42 | 16 | / |
Metformin | 98 | 53 | 49 | 5.33 | -0.22 | ||||||
Pioglitazone | 63 | 52 | 62 | 4.85 | -0.25 | ||||||
Chen [18] | China | Linagliptin | / | 88 | 54 | 59 | / | 8.09 | -0.25 | 24 | 4 |
Ning [19] | China | Vildagliptin | Insulin | 118 | 58.5 | 55 | 11.4 | 8.6 | -0.22 | 24 | 5 |